Kevin A. Kriess

Array ( [id] => 17982626 [patent_doc_number] => 20220348662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => USE OF FGFR INHIBITORS IN FGFR-GENETICALLY ALTERED CANCERS TO ENHANCE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SEQUENTIAL TREATMENT SETTINGS [patent_app_type] => utility [patent_app_number] => 17/763251 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16558430 [patent_doc_number] => 20210003579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => METHOD FOR ASSISTING DETERMINATION OF EFFICACY OF IMMUNE CHECKPOINT INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/029361 [patent_app_country] => US [patent_app_date] => 2020-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17029361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18019065 [patent_doc_number] => 20220370564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => IL-10/fc Fusion Proteins Useful As Enhancers Of Immunotherapies [patent_app_type] => utility [patent_app_number] => 17/760947 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9624 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904157 [patent_doc_number] => 12281153 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Combination therapy with targeted 4-1BB (CD137) agonists [patent_app_type] => utility [patent_app_number] => 17/017942 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 15 [patent_no_of_words] => 45646 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18027811 [patent_doc_number] => 11510972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Bispecific EGFR/CD16 antigen-binding protein [patent_app_type] => utility [patent_app_number] => 17/010622 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 36 [patent_no_of_words] => 23834 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512984 [patent_doc_number] => 20200392242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses [patent_app_type] => utility [patent_app_number] => 17/005734 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17005734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18683933 [patent_doc_number] => 11779643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Methods and compositions for the treatment of an inflammatory bowel disease [patent_app_type] => utility [patent_app_number] => 17/004555 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 9959 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17004555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688386 [patent_doc_number] => 20210070862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => B7-H4 ANTIBODY DOSING REGIMENS [patent_app_type] => utility [patent_app_number] => 16/997581 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657458 [patent_doc_number] => 20210054094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => ANTIBODIES BINDING TO GPRC5D [patent_app_type] => utility [patent_app_number] => 16/944292 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16944292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717879 [patent_doc_number] => 11795210 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => HIV vaccines and methods of making and using [patent_app_type] => utility [patent_app_number] => 16/928571 [patent_app_country] => US [patent_app_date] => 2020-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 76 [patent_no_of_words] => 82693 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16928571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20386617 [patent_doc_number] => 12486334 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Chemically controlled monoclonal antibody target engagement [patent_app_type] => utility [patent_app_number] => 17/626459 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 3211 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17626459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056530 [patent_doc_number] => 20220387616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => SIALIDASE-HER2-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/624124 [patent_app_country] => US [patent_app_date] => 2020-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -80 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971964 [patent_doc_number] => 20240052056 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-02-15 [patent_title] => Targeting Intracellular Target-Binding Determinants with Intracellular Antibodies [patent_app_type] => utility [patent_app_number] => 16/902173 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12065 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971964 [patent_doc_number] => 20240052056 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-02-15 [patent_title] => Targeting Intracellular Target-Binding Determinants with Intracellular Antibodies [patent_app_type] => utility [patent_app_number] => 16/902173 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12065 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805820 [patent_doc_number] => 20220257655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => ENGINEERED OFF-THE-SHELF IMMUNE CELLS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/618240 [patent_app_country] => US [patent_app_date] => 2020-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897373 [patent_doc_number] => 20220307035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => COMPOSITION FOR PREVENTING OR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/596442 [patent_app_country] => US [patent_app_date] => 2020-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671363 [patent_doc_number] => 20210060126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/899512 [patent_app_country] => US [patent_app_date] => 2020-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541037 [patent_doc_number] => 20200407450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => USE OF A CEA CD3 BISPECIFIC ANTIBODY AND A PD-1 AXIS BINDING ANTAGONIST IN A DOSAGE REGIMEN TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 16/898248 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882748 [patent_doc_number] => 20220298225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER WITH COLLAGEN BINDING DRUG CARRIERS [patent_app_type] => utility [patent_app_number] => 17/596118 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748088 [patent_doc_number] => 20220226291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => Combination Treatment of Cancer Using Sulfonamide Compound and Immune Regulator [patent_app_type] => utility [patent_app_number] => 17/614074 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614074 [rel_patent_id] =>[rel_patent_doc_number] =>)